Univariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment
| Characteristic | Patients with SRP after 3 years (Yes/No), n=96 | ||
|---|---|---|---|
| Baseline | N | OR (95% CI) | p Value |
| Age | 96 | 0.72 (0.47 to 1.11) | 0.141 |
| Gender (male/female) | 96 | 1.43 (0.49 to 4.18) | 0.516 |
| Disease duration, years | 96 | 0.74 (0.47 to 1.16) | 0.188 |
| Corticosteroids (Yes/No) | 96 | 0.87 (0.36 to 2.11) | 0.767 |
| Dose of corticosteroids, 0–5 mg/no | 96 | 0.93 (0.32 to 2.71) | 0.982 |
| Dose of corticosteroids, >5 mg/no | 96 | 0.84 (0.31 to 2.26) | 0.760 |
| Swollen joints | 96 | 1.06 (0.69 to 1.61) | 0.800 |
| Tender joints | 96 | 1.10 (0.72 to 1.68) | 0.648 |
| ESR, mm/h | 95 | 2.09 (1.32 to 3.33) | 0.002 |
| CRP, mg/L | 94 | 2.52 (1.51 to 4.20) | <0.001 |
| RF, mg/L | 96 | 2.69 (1.41 to 5.12) | 0.003 |
| RF positive, n (%) | 96 | 4.78 (1.63 to 13.96) | 0.004 |
| HAQ | 96 | 1.22 (0.79 to 1.88) | 0.372 |
| mTSS | 96 | 1.20 (0.79 to 1.81) | 0.391 |
| Erosion score | 96 | 1.17 (0.77 to 1.76) | 0.461 |
| Last observation (months 6–12) | |||
| ESR, mm/h | 95 | 1.69 (1.09 to 2.62) | 0.020 |
| CRP, mg/L | 95 | 1.51 (0.99 to 2.30) | 0.057 |
| RF, mg/L | 96 | 2.09 (1.03 to 4.23) | 0.040 |
| Swollen joints | 96 | 1.58 (1.00 to 2.49) | 0.048 |
| Tender joints | 96 | 1.19 (0.79 to 1.80) | 0.411 |
| HAQ | 96 | 0.93 (0.61 to 1.42) | 0.737 |
| MTX dose, mg/week | 96 | 1.23 (0.77 to 1.96) | 0.387 |
| MTX dose 7.5–10 mg/week or 5–20 mg/week | 96 | 0.95 (0.17 to 5.49) | 0.956 |
CRP, C reactive protein; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; mTSS, modified Sharp/van der Heijde; MTX, methotrexate; RF, rheumatoid factor; SRP, significant radiographic progression.